Pyridone 6

Primary antibodies to IRF1 (1:500 dilution, #8478), Src (1:500 dilution, #2123), and phospho-Src (Y416) (1:500 dilution, #6943) were from Cell Signaling Technology; DYKDDDDK (Clone 1E6, 1:1000 dilution, 018–22381) and GAPDH were from Wako (Clone 5A12; 1:5000 dilution, 016-25523); CSNK2B (1:2000 dilution, A301-984A) and CSNK2A2 (1:2000 dilution, A300-199A) were from Bethyl Laboratories; and CSNK2A1 (1:2000 dilution, 10992-1-AP) and AFAP1 (1:500 dilution, 14544-1-AP) were from Proteintech. IRDye 680 or 800 secondary antibodies including #926-32211, #926-32212, #926-32214, #926-68020 and #926-68073 (1:20 000 dilution) were from LI-COR.
CX-4945 (Silmitasertib) was purchased from Selleck. Puromycin and Hygromycin B Gold were from InvivoGen. Pyridone 6 (JAK Inhibitor I) was from Cayman Chemical. All-trans-retinoic acid was from Wako. Recombinant human IFN-γ and CSNK2B were from Pepro Tech and NKMAX, respectively. PSI-7977 (Sofosbuvir) was from ChemScene. Lambda protein phosphatase was obtained from Bio Academia. miR-122 mimics were synthesized by Dharmacon and transfected by electroporation as miRNA/miRNA* duplexes as described (9 (link)). Cell viability was determined using Cell Counting Kit-8 (DOJINDO, Japan) on 96-well plates according to the manufacturer's protocol.

HyClone high glucose Dulbecco's modified Eagle's medium (DMEM), FBS, and other tissue culture reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA). LPS and MG‐132 were purchased from Sigma‐Aldrich (St Louis, MO, USA). TAK‐242 was purchased from Calbiochem (La Jolla, CA, USA). Pyridone 6 was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Primary antibodies for acetyl‐Lys and HDAC4 and secondary antibodies used for western blot analyses were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Primary antibodies for phospho‐STAT1 and STAT1 were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies for β‐actin and HMGB1 were from Sigma‐Aldrich and Abcam (Cambridge, MA, USA), respectively.